Agios Pharmaceuticals, Inc. $AGIO Stock Holdings Reduced by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company reduced its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 28.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 50,046 shares of the biopharmaceutical company’s stock after selling 20,210 shares during the period. The Manufacturers Life Insurance Company owned about 0.08% of Agios Pharmaceuticals worth $1,693,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Wellington Management Group LLP lifted its holdings in shares of Agios Pharmaceuticals by 485.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after buying an additional 2,049,287 shares during the last quarter. MPM Bioimpact LLC acquired a new position in Agios Pharmaceuticals in the fourth quarter worth approximately $35,478,000. State Street Corp increased its holdings in Agios Pharmaceuticals by 37.4% in the fourth quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock worth $84,604,000 after buying an additional 845,433 shares during the last quarter. TCG Crossover Management LLC raised its position in Agios Pharmaceuticals by 105.2% during the third quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock valued at $57,402,000 after acquiring an additional 733,038 shares in the last quarter. Finally, Capital International Investors bought a new position in Agios Pharmaceuticals during the fourth quarter valued at approximately $19,159,000.

Insider Activity at Agios Pharmaceuticals

In other news, insider Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $30.48, for a total value of $914,400.00. Following the transaction, the insider directly owned 54,645 shares in the company, valued at approximately $1,665,579.60. The trade was a 35.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.40% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on the stock. Citigroup boosted their target price on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Royal Bank Of Canada raised their price target on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “sector perform” rating in a report on Tuesday, July 7th. Truist Financial reduced their price objective on shares of Agios Pharmaceuticals from $41.00 to $39.00 and set a “buy” rating for the company in a research note on Friday, July 31st. JPMorgan Chase & Co. upped their price objective on shares of Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a “neutral” rating in a report on Friday. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, June 24th. Five equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $41.25.

Agios Pharmaceuticals Trading Up 1.0%

NASDAQ AGIO opened at $32.59 on Tuesday. Agios Pharmaceuticals, Inc. has a 1 year low of $22.24 and a 1 year high of $46.00. The company has a fifty day simple moving average of $34.84 and a 200 day simple moving average of $31.08. The company has a market cap of $1.95 billion, a P/E ratio of -4.65 and a beta of 0.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%.The firm had revenue of $44.75 million during the quarter, compared to the consensus estimate of $26.39 million. Equities research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.12 EPS for the current fiscal year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.